nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—CYP3A4—bone cancer	0.519	1	CbGaD
Imipramine—SLC22A2—Cisplatin—bone cancer	0.0598	0.362	CbGbCtD
Imipramine—CYP2B6—Cisplatin—bone cancer	0.031	0.188	CbGbCtD
Imipramine—CYP2B6—Doxorubicin—bone cancer	0.0208	0.126	CbGbCtD
Imipramine—ABCB1—Cisplatin—bone cancer	0.0159	0.0965	CbGbCtD
Imipramine—ABCB1—Doxorubicin—bone cancer	0.0107	0.0646	CbGbCtD
Imipramine—ABCB1—Methotrexate—bone cancer	0.0103	0.0626	CbGbCtD
Imipramine—CYP2D6—Doxorubicin—bone cancer	0.01	0.0609	CbGbCtD
Imipramine—CYP3A4—Doxorubicin—bone cancer	0.00639	0.0387	CbGbCtD
Imipramine—Clomipramine—GSTP1—bone cancer	0.000914	0.114	CrCbGaD
Imipramine—Olopatadine—CYP3A4—bone cancer	0.000669	0.0836	CrCbGaD
Imipramine—Alimemazine—CYP3A4—bone cancer	0.00061	0.0763	CrCbGaD
Imipramine—Cyclobenzaprine—CYP3A4—bone cancer	0.000562	0.0703	CrCbGaD
Imipramine—Epinastine—CYP3A4—bone cancer	0.000558	0.0698	CrCbGaD
Imipramine—Mequitazine—CYP3A4—bone cancer	0.000525	0.0657	CrCbGaD
Imipramine—Oedema—Cisplatin—bone cancer	0.000518	0.00341	CcSEcCtD
Imipramine—Anaphylactic shock—Cisplatin—bone cancer	0.000518	0.00341	CcSEcCtD
Imipramine—Infection—Cisplatin—bone cancer	0.000515	0.00338	CcSEcCtD
Imipramine—Oxcarbazepine—CYP3A4—bone cancer	0.000514	0.0643	CrCbGaD
Imipramine—Cardiac failure—Doxorubicin—bone cancer	0.000513	0.00337	CcSEcCtD
Imipramine—Mood swings—Epirubicin—bone cancer	0.000513	0.00337	CcSEcCtD
Imipramine—Cerebrovascular accident—Doxorubicin—bone cancer	0.000511	0.00336	CcSEcCtD
Imipramine—Ataxia—Epirubicin—bone cancer	0.000509	0.00335	CcSEcCtD
Imipramine—Nervous system disorder—Cisplatin—bone cancer	0.000508	0.00334	CcSEcCtD
Imipramine—Thrombocytopenia—Cisplatin—bone cancer	0.000507	0.00333	CcSEcCtD
Imipramine—Tachycardia—Cisplatin—bone cancer	0.000506	0.00332	CcSEcCtD
Imipramine—Skin disorder—Cisplatin—bone cancer	0.000503	0.00331	CcSEcCtD
Imipramine—Hyperhidrosis—Cisplatin—bone cancer	0.000501	0.00329	CcSEcCtD
Imipramine—Liver function test abnormal—Epirubicin—bone cancer	0.0005	0.00329	CcSEcCtD
Imipramine—Eosinophilia—Methotrexate—bone cancer	0.000495	0.00325	CcSEcCtD
Imipramine—Orthostatic hypotension—Epirubicin—bone cancer	0.000494	0.00325	CcSEcCtD
Imipramine—Anorexia—Cisplatin—bone cancer	0.000494	0.00325	CcSEcCtD
Imipramine—Affect lability—Doxorubicin—bone cancer	0.000493	0.00324	CcSEcCtD
Imipramine—Breast disorder—Epirubicin—bone cancer	0.000489	0.00322	CcSEcCtD
Imipramine—Pancytopenia—Methotrexate—bone cancer	0.000475	0.00312	CcSEcCtD
Imipramine—Mood swings—Doxorubicin—bone cancer	0.000475	0.00312	CcSEcCtD
Imipramine—Ataxia—Doxorubicin—bone cancer	0.000471	0.0031	CcSEcCtD
Imipramine—Paraesthesia—Cisplatin—bone cancer	0.000465	0.00306	CcSEcCtD
Imipramine—Eosinophilia—Epirubicin—bone cancer	0.000463	0.00305	CcSEcCtD
Imipramine—Liver function test abnormal—Doxorubicin—bone cancer	0.000462	0.00304	CcSEcCtD
Imipramine—Erectile dysfunction—Methotrexate—bone cancer	0.00046	0.00303	CcSEcCtD
Imipramine—Orthostatic hypotension—Doxorubicin—bone cancer	0.000458	0.00301	CcSEcCtD
Imipramine—Photosensitivity reaction—Methotrexate—bone cancer	0.000456	0.003	CcSEcCtD
Imipramine—Breast disorder—Doxorubicin—bone cancer	0.000453	0.00298	CcSEcCtD
Imipramine—Decreased appetite—Cisplatin—bone cancer	0.00045	0.00296	CcSEcCtD
Imipramine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000447	0.00294	CcSEcCtD
Imipramine—Infestation—Methotrexate—bone cancer	0.000446	0.00293	CcSEcCtD
Imipramine—Drowsiness—Methotrexate—bone cancer	0.000446	0.00293	CcSEcCtD
Imipramine—Infestation NOS—Methotrexate—bone cancer	0.000446	0.00293	CcSEcCtD
Imipramine—Pancytopenia—Epirubicin—bone cancer	0.000444	0.00292	CcSEcCtD
Imipramine—Stomatitis—Methotrexate—bone cancer	0.000435	0.00286	CcSEcCtD
Imipramine—Pollakiuria—Epirubicin—bone cancer	0.000432	0.00284	CcSEcCtD
Imipramine—Eosinophilia—Doxorubicin—bone cancer	0.000429	0.00282	CcSEcCtD
Imipramine—Photosensitivity reaction—Epirubicin—bone cancer	0.000427	0.00281	CcSEcCtD
Imipramine—Feeling abnormal—Cisplatin—bone cancer	0.000427	0.00281	CcSEcCtD
Imipramine—Weight increased—Epirubicin—bone cancer	0.000426	0.0028	CcSEcCtD
Imipramine—Weight decreased—Epirubicin—bone cancer	0.000423	0.00278	CcSEcCtD
Imipramine—Hepatobiliary disease—Methotrexate—bone cancer	0.000422	0.00277	CcSEcCtD
Imipramine—Infestation NOS—Epirubicin—bone cancer	0.000417	0.00274	CcSEcCtD
Imipramine—Drowsiness—Epirubicin—bone cancer	0.000417	0.00274	CcSEcCtD
Imipramine—Infestation—Epirubicin—bone cancer	0.000417	0.00274	CcSEcCtD
Imipramine—Agranulocytosis—Methotrexate—bone cancer	0.000416	0.00273	CcSEcCtD
Imipramine—Pancytopenia—Doxorubicin—bone cancer	0.000411	0.0027	CcSEcCtD
Imipramine—Body temperature increased—Cisplatin—bone cancer	0.00041	0.00269	CcSEcCtD
Imipramine—Neuropathy peripheral—Epirubicin—bone cancer	0.000409	0.00269	CcSEcCtD
Imipramine—Stomatitis—Epirubicin—bone cancer	0.000407	0.00267	CcSEcCtD
Imipramine—Jaundice—Epirubicin—bone cancer	0.000407	0.00267	CcSEcCtD
Imipramine—Hepatitis—Methotrexate—bone cancer	0.0004	0.00263	CcSEcCtD
Imipramine—Pollakiuria—Doxorubicin—bone cancer	0.0004	0.00263	CcSEcCtD
Imipramine—Urinary tract disorder—Methotrexate—bone cancer	0.000395	0.0026	CcSEcCtD
Imipramine—Photosensitivity reaction—Doxorubicin—bone cancer	0.000395	0.0026	CcSEcCtD
Imipramine—Hepatobiliary disease—Epirubicin—bone cancer	0.000395	0.00259	CcSEcCtD
Imipramine—Weight increased—Doxorubicin—bone cancer	0.000394	0.00259	CcSEcCtD
Imipramine—Urethral disorder—Methotrexate—bone cancer	0.000392	0.00258	CcSEcCtD
Imipramine—Weight decreased—Doxorubicin—bone cancer	0.000392	0.00257	CcSEcCtD
Imipramine—Agranulocytosis—Epirubicin—bone cancer	0.000389	0.00256	CcSEcCtD
Imipramine—Drowsiness—Doxorubicin—bone cancer	0.000386	0.00254	CcSEcCtD
Imipramine—Infestation NOS—Doxorubicin—bone cancer	0.000386	0.00254	CcSEcCtD
Imipramine—Infestation—Doxorubicin—bone cancer	0.000386	0.00254	CcSEcCtD
Imipramine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000378	0.00249	CcSEcCtD
Imipramine—Stomatitis—Doxorubicin—bone cancer	0.000376	0.00247	CcSEcCtD
Imipramine—Jaundice—Doxorubicin—bone cancer	0.000376	0.00247	CcSEcCtD
Imipramine—Hepatitis—Epirubicin—bone cancer	0.000375	0.00246	CcSEcCtD
Imipramine—Eye disorder—Methotrexate—bone cancer	0.000374	0.00246	CcSEcCtD
Imipramine—Pipotiazine—CYP3A4—bone cancer	0.000374	0.0467	CrCbGaD
Imipramine—Tinnitus—Methotrexate—bone cancer	0.000373	0.00245	CcSEcCtD
Imipramine—Hypoaesthesia—Epirubicin—bone cancer	0.000373	0.00245	CcSEcCtD
Imipramine—Asthenia—Cisplatin—bone cancer	0.000372	0.00244	CcSEcCtD
Imipramine—Cardiac disorder—Methotrexate—bone cancer	0.000371	0.00244	CcSEcCtD
Imipramine—Urinary tract disorder—Epirubicin—bone cancer	0.00037	0.00243	CcSEcCtD
Imipramine—Urethral disorder—Epirubicin—bone cancer	0.000367	0.00241	CcSEcCtD
Imipramine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000365	0.0024	CcSEcCtD
Imipramine—Angiopathy—Methotrexate—bone cancer	0.000363	0.00239	CcSEcCtD
Imipramine—Immune system disorder—Methotrexate—bone cancer	0.000361	0.00238	CcSEcCtD
Imipramine—Mediastinal disorder—Methotrexate—bone cancer	0.000361	0.00237	CcSEcCtD
Imipramine—Agranulocytosis—Doxorubicin—bone cancer	0.00036	0.00237	CcSEcCtD
Imipramine—Prochlorperazine—CYP3A4—bone cancer	0.000357	0.0447	CrCbGaD
Imipramine—Diarrhoea—Cisplatin—bone cancer	0.000355	0.00233	CcSEcCtD
Imipramine—Alopecia—Methotrexate—bone cancer	0.000354	0.00232	CcSEcCtD
Imipramine—Mental disorder—Methotrexate—bone cancer	0.000351	0.0023	CcSEcCtD
Imipramine—Carbamazepine—CYP3A4—bone cancer	0.00035	0.0438	CrCbGaD
Imipramine—Eye disorder—Epirubicin—bone cancer	0.00035	0.0023	CcSEcCtD
Imipramine—Tinnitus—Epirubicin—bone cancer	0.000349	0.0023	CcSEcCtD
Imipramine—Malnutrition—Methotrexate—bone cancer	0.000348	0.00229	CcSEcCtD
Imipramine—Flushing—Epirubicin—bone cancer	0.000348	0.00228	CcSEcCtD
Imipramine—Cardiac disorder—Epirubicin—bone cancer	0.000348	0.00228	CcSEcCtD
Imipramine—Hepatitis—Doxorubicin—bone cancer	0.000347	0.00228	CcSEcCtD
Imipramine—Hypoaesthesia—Doxorubicin—bone cancer	0.000345	0.00227	CcSEcCtD
Imipramine—Urinary tract disorder—Doxorubicin—bone cancer	0.000342	0.00225	CcSEcCtD
Imipramine—Dysgeusia—Methotrexate—bone cancer	0.000341	0.00224	CcSEcCtD
Imipramine—Angiopathy—Epirubicin—bone cancer	0.00034	0.00223	CcSEcCtD
Imipramine—Urethral disorder—Doxorubicin—bone cancer	0.00034	0.00223	CcSEcCtD
Imipramine—Immune system disorder—Epirubicin—bone cancer	0.000338	0.00222	CcSEcCtD
Imipramine—Mediastinal disorder—Epirubicin—bone cancer	0.000338	0.00222	CcSEcCtD
Imipramine—Arrhythmia—Epirubicin—bone cancer	0.000335	0.0022	CcSEcCtD
Imipramine—Alopecia—Epirubicin—bone cancer	0.000331	0.00218	CcSEcCtD
Imipramine—Vomiting—Cisplatin—bone cancer	0.000329	0.00217	CcSEcCtD
Imipramine—Vision blurred—Methotrexate—bone cancer	0.000328	0.00216	CcSEcCtD
Imipramine—Mental disorder—Epirubicin—bone cancer	0.000328	0.00216	CcSEcCtD
Imipramine—Rash—Cisplatin—bone cancer	0.000327	0.00215	CcSEcCtD
Imipramine—Dermatitis—Cisplatin—bone cancer	0.000326	0.00215	CcSEcCtD
Imipramine—Malnutrition—Epirubicin—bone cancer	0.000326	0.00214	CcSEcCtD
Imipramine—Eye disorder—Doxorubicin—bone cancer	0.000324	0.00213	CcSEcCtD
Imipramine—Ill-defined disorder—Methotrexate—bone cancer	0.000323	0.00212	CcSEcCtD
Imipramine—Tinnitus—Doxorubicin—bone cancer	0.000323	0.00212	CcSEcCtD
Imipramine—Mianserin—CYP3A4—bone cancer	0.000323	0.0404	CrCbGaD
Imipramine—Flushing—Doxorubicin—bone cancer	0.000322	0.00211	CcSEcCtD
Imipramine—Cardiac disorder—Doxorubicin—bone cancer	0.000322	0.00211	CcSEcCtD
Imipramine—Tension—Epirubicin—bone cancer	0.00032	0.0021	CcSEcCtD
Imipramine—Dysgeusia—Epirubicin—bone cancer	0.000319	0.0021	CcSEcCtD
Imipramine—Nervousness—Epirubicin—bone cancer	0.000317	0.00208	CcSEcCtD
Imipramine—Angiopathy—Doxorubicin—bone cancer	0.000314	0.00207	CcSEcCtD
Imipramine—Malaise—Methotrexate—bone cancer	0.000314	0.00207	CcSEcCtD
Imipramine—Immune system disorder—Doxorubicin—bone cancer	0.000313	0.00206	CcSEcCtD
Imipramine—Mediastinal disorder—Doxorubicin—bone cancer	0.000312	0.00205	CcSEcCtD
Imipramine—Leukopenia—Methotrexate—bone cancer	0.000312	0.00205	CcSEcCtD
Imipramine—Arrhythmia—Doxorubicin—bone cancer	0.00031	0.00203	CcSEcCtD
Imipramine—Nausea—Cisplatin—bone cancer	0.000308	0.00202	CcSEcCtD
Imipramine—Vision blurred—Epirubicin—bone cancer	0.000307	0.00202	CcSEcCtD
Imipramine—Alopecia—Doxorubicin—bone cancer	0.000306	0.00201	CcSEcCtD
Imipramine—Mental disorder—Doxorubicin—bone cancer	0.000304	0.002	CcSEcCtD
Imipramine—Ill-defined disorder—Epirubicin—bone cancer	0.000303	0.00199	CcSEcCtD
Imipramine—Convulsion—Methotrexate—bone cancer	0.000302	0.00198	CcSEcCtD
Imipramine—Malnutrition—Doxorubicin—bone cancer	0.000302	0.00198	CcSEcCtD
Imipramine—Agitation—Epirubicin—bone cancer	0.0003	0.00197	CcSEcCtD
Imipramine—Tension—Doxorubicin—bone cancer	0.000296	0.00195	CcSEcCtD
Imipramine—Dysgeusia—Doxorubicin—bone cancer	0.000295	0.00194	CcSEcCtD
Imipramine—Clomipramine—CYP3A4—bone cancer	0.000295	0.0369	CrCbGaD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000295	0.00194	CcSEcCtD
Imipramine—Malaise—Epirubicin—bone cancer	0.000294	0.00193	CcSEcCtD
Imipramine—Discomfort—Methotrexate—bone cancer	0.000293	0.00193	CcSEcCtD
Imipramine—Nervousness—Doxorubicin—bone cancer	0.000293	0.00193	CcSEcCtD
Imipramine—Syncope—Epirubicin—bone cancer	0.000292	0.00192	CcSEcCtD
Imipramine—Leukopenia—Epirubicin—bone cancer	0.000292	0.00192	CcSEcCtD
Imipramine—Nortriptyline—CYP3A4—bone cancer	0.000289	0.0361	CrCbGaD
Imipramine—Palpitations—Epirubicin—bone cancer	0.000288	0.00189	CcSEcCtD
Imipramine—Confusional state—Methotrexate—bone cancer	0.000287	0.00188	CcSEcCtD
Imipramine—Loss of consciousness—Epirubicin—bone cancer	0.000287	0.00188	CcSEcCtD
Imipramine—Anaphylactic shock—Methotrexate—bone cancer	0.000284	0.00187	CcSEcCtD
Imipramine—Vision blurred—Doxorubicin—bone cancer	0.000284	0.00187	CcSEcCtD
Imipramine—Convulsion—Epirubicin—bone cancer	0.000282	0.00186	CcSEcCtD
Imipramine—Infection—Methotrexate—bone cancer	0.000282	0.00186	CcSEcCtD
Imipramine—Hypertension—Epirubicin—bone cancer	0.000281	0.00185	CcSEcCtD
Imipramine—Ill-defined disorder—Doxorubicin—bone cancer	0.00028	0.00184	CcSEcCtD
Imipramine—Nervous system disorder—Methotrexate—bone cancer	0.000279	0.00183	CcSEcCtD
Imipramine—Thrombocytopenia—Methotrexate—bone cancer	0.000278	0.00183	CcSEcCtD
Imipramine—Agitation—Doxorubicin—bone cancer	0.000277	0.00182	CcSEcCtD
Imipramine—Anxiety—Epirubicin—bone cancer	0.000277	0.00182	CcSEcCtD
Imipramine—Skin disorder—Methotrexate—bone cancer	0.000276	0.00182	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000276	0.00181	CcSEcCtD
Imipramine—Hyperhidrosis—Methotrexate—bone cancer	0.000275	0.00181	CcSEcCtD
Imipramine—Discomfort—Epirubicin—bone cancer	0.000274	0.0018	CcSEcCtD
Imipramine—Malaise—Doxorubicin—bone cancer	0.000272	0.00179	CcSEcCtD
Imipramine—Trimipramine—CYP3A4—bone cancer	0.000272	0.034	CrCbGaD
Imipramine—Dry mouth—Epirubicin—bone cancer	0.000271	0.00178	CcSEcCtD
Imipramine—Anorexia—Methotrexate—bone cancer	0.000271	0.00178	CcSEcCtD
Imipramine—Syncope—Doxorubicin—bone cancer	0.000271	0.00178	CcSEcCtD
Imipramine—Leukopenia—Doxorubicin—bone cancer	0.00027	0.00177	CcSEcCtD
Imipramine—Confusional state—Epirubicin—bone cancer	0.000268	0.00176	CcSEcCtD
Imipramine—Palpitations—Doxorubicin—bone cancer	0.000267	0.00175	CcSEcCtD
Imipramine—Anaphylactic shock—Epirubicin—bone cancer	0.000266	0.00175	CcSEcCtD
Imipramine—Oedema—Epirubicin—bone cancer	0.000266	0.00175	CcSEcCtD
Imipramine—Loss of consciousness—Doxorubicin—bone cancer	0.000265	0.00174	CcSEcCtD
Imipramine—Infection—Epirubicin—bone cancer	0.000264	0.00174	CcSEcCtD
Imipramine—Shock—Epirubicin—bone cancer	0.000262	0.00172	CcSEcCtD
Imipramine—Convulsion—Doxorubicin—bone cancer	0.000261	0.00172	CcSEcCtD
Imipramine—Nervous system disorder—Epirubicin—bone cancer	0.000261	0.00172	CcSEcCtD
Imipramine—Thrombocytopenia—Epirubicin—bone cancer	0.000261	0.00171	CcSEcCtD
Imipramine—Hypertension—Doxorubicin—bone cancer	0.00026	0.00171	CcSEcCtD
Imipramine—Tachycardia—Epirubicin—bone cancer	0.00026	0.00171	CcSEcCtD
Imipramine—Doxepin—CYP3A4—bone cancer	0.000259	0.0324	CrCbGaD
Imipramine—Skin disorder—Epirubicin—bone cancer	0.000258	0.0017	CcSEcCtD
Imipramine—Hyperhidrosis—Epirubicin—bone cancer	0.000257	0.00169	CcSEcCtD
Imipramine—Insomnia—Methotrexate—bone cancer	0.000257	0.00169	CcSEcCtD
Imipramine—Anxiety—Doxorubicin—bone cancer	0.000256	0.00168	CcSEcCtD
Imipramine—Paraesthesia—Methotrexate—bone cancer	0.000255	0.00168	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000255	0.00168	CcSEcCtD
Imipramine—Discomfort—Doxorubicin—bone cancer	0.000254	0.00167	CcSEcCtD
Imipramine—Anorexia—Epirubicin—bone cancer	0.000254	0.00167	CcSEcCtD
Imipramine—Somnolence—Methotrexate—bone cancer	0.000253	0.00166	CcSEcCtD
Imipramine—Orphenadrine—CYP3A4—bone cancer	0.000252	0.0316	CrCbGaD
Imipramine—Dry mouth—Doxorubicin—bone cancer	0.000251	0.00165	CcSEcCtD
Imipramine—Dyspepsia—Methotrexate—bone cancer	0.00025	0.00165	CcSEcCtD
Imipramine—Confusional state—Doxorubicin—bone cancer	0.000248	0.00163	CcSEcCtD
Imipramine—Decreased appetite—Methotrexate—bone cancer	0.000247	0.00162	CcSEcCtD
Imipramine—Anaphylactic shock—Doxorubicin—bone cancer	0.000246	0.00162	CcSEcCtD
Imipramine—Oedema—Doxorubicin—bone cancer	0.000246	0.00162	CcSEcCtD
Imipramine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000245	0.00161	CcSEcCtD
Imipramine—Fatigue—Methotrexate—bone cancer	0.000245	0.00161	CcSEcCtD
Imipramine—Infection—Doxorubicin—bone cancer	0.000245	0.00161	CcSEcCtD
Imipramine—Shock—Doxorubicin—bone cancer	0.000242	0.00159	CcSEcCtD
Imipramine—Nervous system disorder—Doxorubicin—bone cancer	0.000241	0.00159	CcSEcCtD
Imipramine—Thrombocytopenia—Doxorubicin—bone cancer	0.000241	0.00158	CcSEcCtD
Imipramine—Insomnia—Epirubicin—bone cancer	0.000241	0.00158	CcSEcCtD
Imipramine—Tachycardia—Doxorubicin—bone cancer	0.00024	0.00158	CcSEcCtD
Imipramine—Skin disorder—Doxorubicin—bone cancer	0.000239	0.00157	CcSEcCtD
Imipramine—Paraesthesia—Epirubicin—bone cancer	0.000239	0.00157	CcSEcCtD
Imipramine—Hyperhidrosis—Doxorubicin—bone cancer	0.000238	0.00156	CcSEcCtD
Imipramine—Desipramine—CYP3A4—bone cancer	0.000238	0.0297	CrCbGaD
Imipramine—Somnolence—Epirubicin—bone cancer	0.000237	0.00155	CcSEcCtD
Imipramine—Anorexia—Doxorubicin—bone cancer	0.000235	0.00154	CcSEcCtD
Imipramine—Feeling abnormal—Methotrexate—bone cancer	0.000234	0.00154	CcSEcCtD
Imipramine—Dyspepsia—Epirubicin—bone cancer	0.000234	0.00154	CcSEcCtD
Imipramine—Gastrointestinal pain—Methotrexate—bone cancer	0.000233	0.00153	CcSEcCtD
Imipramine—Decreased appetite—Epirubicin—bone cancer	0.000231	0.00152	CcSEcCtD
Imipramine—Promazine—CYP3A4—bone cancer	0.00023	0.0288	CrCbGaD
Imipramine—Gastrointestinal disorder—Epirubicin—bone cancer	0.00023	0.00151	CcSEcCtD
Imipramine—Fatigue—Epirubicin—bone cancer	0.000229	0.00151	CcSEcCtD
Imipramine—Constipation—Epirubicin—bone cancer	0.000228	0.0015	CcSEcCtD
Imipramine—Urticaria—Methotrexate—bone cancer	0.000226	0.00148	CcSEcCtD
Imipramine—Abdominal pain—Methotrexate—bone cancer	0.000225	0.00148	CcSEcCtD
Imipramine—Body temperature increased—Methotrexate—bone cancer	0.000225	0.00148	CcSEcCtD
Imipramine—Insomnia—Doxorubicin—bone cancer	0.000223	0.00146	CcSEcCtD
Imipramine—Paraesthesia—Doxorubicin—bone cancer	0.000221	0.00145	CcSEcCtD
Imipramine—Feeling abnormal—Epirubicin—bone cancer	0.000219	0.00144	CcSEcCtD
Imipramine—Somnolence—Doxorubicin—bone cancer	0.000219	0.00144	CcSEcCtD
Imipramine—Gastrointestinal pain—Epirubicin—bone cancer	0.000218	0.00143	CcSEcCtD
Imipramine—Dyspepsia—Doxorubicin—bone cancer	0.000217	0.00142	CcSEcCtD
Imipramine—Decreased appetite—Doxorubicin—bone cancer	0.000214	0.00141	CcSEcCtD
Imipramine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000213	0.0014	CcSEcCtD
Imipramine—Fatigue—Doxorubicin—bone cancer	0.000212	0.0014	CcSEcCtD
Imipramine—Urticaria—Epirubicin—bone cancer	0.000211	0.00139	CcSEcCtD
Imipramine—Constipation—Doxorubicin—bone cancer	0.000211	0.00138	CcSEcCtD
Imipramine—Body temperature increased—Epirubicin—bone cancer	0.00021	0.00138	CcSEcCtD
Imipramine—Abdominal pain—Epirubicin—bone cancer	0.00021	0.00138	CcSEcCtD
Imipramine—Asthenia—Methotrexate—bone cancer	0.000204	0.00134	CcSEcCtD
Imipramine—Feeling abnormal—Doxorubicin—bone cancer	0.000203	0.00133	CcSEcCtD
Imipramine—Chlorpromazine—CYP3A4—bone cancer	0.000203	0.0253	CrCbGaD
Imipramine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000201	0.00132	CcSEcCtD
Imipramine—Pruritus—Methotrexate—bone cancer	0.000201	0.00132	CcSEcCtD
Imipramine—Amitriptyline—CYP3A4—bone cancer	0.0002	0.0251	CrCbGaD
Imipramine—Urticaria—Doxorubicin—bone cancer	0.000196	0.00129	CcSEcCtD
Imipramine—Abdominal pain—Doxorubicin—bone cancer	0.000195	0.00128	CcSEcCtD
Imipramine—Body temperature increased—Doxorubicin—bone cancer	0.000195	0.00128	CcSEcCtD
Imipramine—Diarrhoea—Methotrexate—bone cancer	0.000195	0.00128	CcSEcCtD
Imipramine—Asthenia—Epirubicin—bone cancer	0.000191	0.00125	CcSEcCtD
Imipramine—Pruritus—Epirubicin—bone cancer	0.000188	0.00124	CcSEcCtD
Imipramine—Dizziness—Methotrexate—bone cancer	0.000188	0.00124	CcSEcCtD
Imipramine—Diarrhoea—Epirubicin—bone cancer	0.000182	0.0012	CcSEcCtD
Imipramine—Vomiting—Methotrexate—bone cancer	0.000181	0.00119	CcSEcCtD
Imipramine—Rash—Methotrexate—bone cancer	0.000179	0.00118	CcSEcCtD
Imipramine—Dermatitis—Methotrexate—bone cancer	0.000179	0.00118	CcSEcCtD
Imipramine—Headache—Methotrexate—bone cancer	0.000178	0.00117	CcSEcCtD
Imipramine—Asthenia—Doxorubicin—bone cancer	0.000177	0.00116	CcSEcCtD
Imipramine—Dizziness—Epirubicin—bone cancer	0.000176	0.00116	CcSEcCtD
Imipramine—Pruritus—Doxorubicin—bone cancer	0.000174	0.00114	CcSEcCtD
Imipramine—Vomiting—Epirubicin—bone cancer	0.000169	0.00111	CcSEcCtD
Imipramine—Nausea—Methotrexate—bone cancer	0.000169	0.00111	CcSEcCtD
Imipramine—Diarrhoea—Doxorubicin—bone cancer	0.000168	0.00111	CcSEcCtD
Imipramine—Rash—Epirubicin—bone cancer	0.000168	0.0011	CcSEcCtD
Imipramine—Dermatitis—Epirubicin—bone cancer	0.000168	0.0011	CcSEcCtD
Imipramine—Headache—Epirubicin—bone cancer	0.000167	0.0011	CcSEcCtD
Imipramine—Dizziness—Doxorubicin—bone cancer	0.000163	0.00107	CcSEcCtD
Imipramine—Nausea—Epirubicin—bone cancer	0.000158	0.00104	CcSEcCtD
Imipramine—Vomiting—Doxorubicin—bone cancer	0.000157	0.00103	CcSEcCtD
Imipramine—Rash—Doxorubicin—bone cancer	0.000155	0.00102	CcSEcCtD
Imipramine—Dermatitis—Doxorubicin—bone cancer	0.000155	0.00102	CcSEcCtD
Imipramine—Headache—Doxorubicin—bone cancer	0.000154	0.00101	CcSEcCtD
Imipramine—Nausea—Doxorubicin—bone cancer	0.000146	0.000961	CcSEcCtD
Imipramine—SLC22A2—Metabolism—CYP3A4—bone cancer	3.24e-05	0.000208	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—ATF1—bone cancer	3.21e-05	0.000206	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—NT5C3A—bone cancer	3.17e-05	0.000204	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TGFBR2—bone cancer	3.15e-05	0.000202	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TGFBR2—bone cancer	3.15e-05	0.000202	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—SMO—bone cancer	3.13e-05	0.000201	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IL3—bone cancer	3.13e-05	0.000201	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—GNA11—bone cancer	3.08e-05	0.000198	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—ENO2—bone cancer	3.06e-05	0.000196	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—CYP3A4—bone cancer	3.02e-05	0.000194	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—GNA11—bone cancer	3.01e-05	0.000193	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—ENO2—bone cancer	2.99e-05	0.000192	CbGpPWpGaD
Imipramine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.99e-05	0.000192	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—GNA11—bone cancer	2.99e-05	0.000192	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TGFBR2—bone cancer	2.97e-05	0.000191	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—IGF1R—bone cancer	2.96e-05	0.00019	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—IGF1R—bone cancer	2.96e-05	0.00019	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—SMO—bone cancer	2.89e-05	0.000185	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—GNA11—bone cancer	2.86e-05	0.000184	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TGFBR2—bone cancer	2.85e-05	0.000183	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—SMO—bone cancer	2.84e-05	0.000182	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—DHFR—bone cancer	2.84e-05	0.000182	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—SMO—bone cancer	2.83e-05	0.000182	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SMO—bone cancer	2.83e-05	0.000181	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SMO—bone cancer	2.82e-05	0.000181	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—ATF1—bone cancer	2.8e-05	0.00018	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IGF1R—bone cancer	2.8e-05	0.00018	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—CYP3A4—bone cancer	2.79e-05	0.000179	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SMO—bone cancer	2.79e-05	0.000179	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SMO—bone cancer	2.78e-05	0.000179	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—ATF1—bone cancer	2.78e-05	0.000179	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—GSTP1—bone cancer	2.78e-05	0.000178	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—DHFR—bone cancer	2.78e-05	0.000178	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—GSTP1—bone cancer	2.77e-05	0.000178	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL3—bone cancer	2.73e-05	0.000175	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL3—bone cancer	2.71e-05	0.000174	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IGF1R—bone cancer	2.68e-05	0.000172	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TGFBR2—bone cancer	2.68e-05	0.000172	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—ATF1—bone cancer	2.66e-05	0.000171	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—GNA11—bone cancer	2.65e-05	0.00017	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—GNA11—bone cancer	2.64e-05	0.00017	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—GNA11—bone cancer	2.6e-05	0.000167	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL3—bone cancer	2.6e-05	0.000167	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—GNA11—bone cancer	2.6e-05	0.000167	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—GNA11—bone cancer	2.59e-05	0.000166	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—GSTP1—bone cancer	2.59e-05	0.000166	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—GNA11—bone cancer	2.58e-05	0.000166	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—GNA11—bone cancer	2.58e-05	0.000165	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—GNA11—bone cancer	2.55e-05	0.000164	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—GNA11—bone cancer	2.54e-05	0.000163	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IGF1R—bone cancer	2.52e-05	0.000162	CbGpPWpGaD
Imipramine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.51e-05	0.000161	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—ATF1—bone cancer	2.45e-05	0.000158	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—ATF1—bone cancer	2.42e-05	0.000155	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—ATF1—bone cancer	2.41e-05	0.000155	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—CYP3A4—bone cancer	2.4e-05	0.000154	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—ATF1—bone cancer	2.4e-05	0.000154	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—ATF1—bone cancer	2.39e-05	0.000154	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL3—bone cancer	2.39e-05	0.000154	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—GSTP1—bone cancer	2.39e-05	0.000153	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—ATF1—bone cancer	2.37e-05	0.000152	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—ATF1—bone cancer	2.36e-05	0.000152	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL3—bone cancer	2.36e-05	0.000151	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—CYP3A4—bone cancer	2.35e-05	0.000151	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL3—bone cancer	2.35e-05	0.000151	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL3—bone cancer	2.34e-05	0.00015	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL3—bone cancer	2.34e-05	0.00015	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TGFBR2—bone cancer	2.33e-05	0.00015	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TGFBR2—bone cancer	2.32e-05	0.000149	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL3—bone cancer	2.31e-05	0.000149	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—ENO2—bone cancer	2.31e-05	0.000148	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL3—bone cancer	2.31e-05	0.000148	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—PTGS2—bone cancer	2.29e-05	0.000147	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—ENO2—bone cancer	2.25e-05	0.000145	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TGFBR2—bone cancer	2.22e-05	0.000143	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IGF1R—bone cancer	2.19e-05	0.000141	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IGF1R—bone cancer	2.18e-05	0.00014	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—PTGS2—bone cancer	2.17e-05	0.000139	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—KIT—bone cancer	2.15e-05	0.000138	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—KIT—bone cancer	2.15e-05	0.000138	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—DHFR—bone cancer	2.14e-05	0.000138	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—ENO2—bone cancer	2.12e-05	0.000136	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—DHFR—bone cancer	2.09e-05	0.000134	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IGF1R—bone cancer	2.09e-05	0.000134	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—GSTP1—bone cancer	2.05e-05	0.000132	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TGFBR2—bone cancer	2.05e-05	0.000131	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—KIT—bone cancer	2.03e-05	0.00013	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—BRAF—bone cancer	2.02e-05	0.00013	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—BRAF—bone cancer	2.02e-05	0.00013	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TGFBR2—bone cancer	2.01e-05	0.000129	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—GSTP1—bone cancer	2.01e-05	0.000129	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TGFBR2—bone cancer	2.01e-05	0.000129	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TGFBR2—bone cancer	2e-05	0.000129	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—GNA11—bone cancer	2e-05	0.000129	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TGFBR2—bone cancer	2e-05	0.000128	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TGFBR2—bone cancer	1.98e-05	0.000127	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TGFBR2—bone cancer	1.97e-05	0.000127	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—DHFR—bone cancer	1.97e-05	0.000127	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—EGFR—bone cancer	1.96e-05	0.000126	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—EGFR—bone cancer	1.96e-05	0.000126	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—GNA11—bone cancer	1.95e-05	0.000126	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—KIT—bone cancer	1.94e-05	0.000125	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IGF1R—bone cancer	1.93e-05	0.000124	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—BRAF—bone cancer	1.91e-05	0.000122	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IGF1R—bone cancer	1.9e-05	0.000122	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IGF1R—bone cancer	1.89e-05	0.000121	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IGF1R—bone cancer	1.89e-05	0.000121	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IGF1R—bone cancer	1.88e-05	0.000121	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IGF1R—bone cancer	1.86e-05	0.000119	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IGF1R—bone cancer	1.86e-05	0.000119	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—EGFR—bone cancer	1.85e-05	0.000119	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—GNA11—bone cancer	1.84e-05	0.000118	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KIT—bone cancer	1.83e-05	0.000117	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—BRAF—bone cancer	1.83e-05	0.000117	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—CYP3A4—bone cancer	1.82e-05	0.000117	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.81e-05	0.000116	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—ENO2—bone cancer	1.8e-05	0.000116	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—CYP3A4—bone cancer	1.77e-05	0.000114	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—EGFR—bone cancer	1.77e-05	0.000114	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—BRAF—bone cancer	1.72e-05	0.00011	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—MDM2—bone cancer	1.69e-05	0.000109	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—MDM2—bone cancer	1.69e-05	0.000109	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.67e-05	0.000107	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—DHFR—bone cancer	1.67e-05	0.000107	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—EGFR—bone cancer	1.66e-05	0.000107	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—MDM2—bone cancer	1.6e-05	0.000103	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KIT—bone cancer	1.59e-05	0.000102	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KIT—bone cancer	1.58e-05	0.000102	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GNA11—bone cancer	1.56e-05	0.0001	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—GSTP1—bone cancer	1.55e-05	9.97e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—MDM2—bone cancer	1.53e-05	9.82e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—GSTP1—bone cancer	1.52e-05	9.73e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KIT—bone cancer	1.52e-05	9.73e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—BRAF—bone cancer	1.5e-05	9.6e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—BRAF—bone cancer	1.49e-05	9.55e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—JUN—bone cancer	1.47e-05	9.45e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—JUN—bone cancer	1.47e-05	9.44e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—EGFR—bone cancer	1.45e-05	9.31e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—EGFR—bone cancer	1.44e-05	9.26e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PTGS2—bone cancer	1.44e-05	9.24e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MDM2—bone cancer	1.44e-05	9.23e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PTGS2—bone cancer	1.44e-05	9.23e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—MMP9—bone cancer	1.43e-05	9.19e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—MMP9—bone cancer	1.43e-05	9.18e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—GSTP1—bone cancer	1.43e-05	9.17e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—BRAF—bone cancer	1.42e-05	9.15e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CYP3A4—bone cancer	1.41e-05	9.08e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.41e-05	9.04e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KIT—bone cancer	1.4e-05	8.97e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ENO2—bone cancer	1.39e-05	8.92e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—JUN—bone cancer	1.39e-05	8.91e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—EGFR—bone cancer	1.38e-05	8.86e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KIT—bone cancer	1.37e-05	8.83e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KIT—bone cancer	1.37e-05	8.81e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KIT—bone cancer	1.37e-05	8.78e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KIT—bone cancer	1.36e-05	8.75e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—MMP9—bone cancer	1.35e-05	8.67e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KIT—bone cancer	1.35e-05	8.67e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KIT—bone cancer	1.35e-05	8.64e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PTGS2—bone cancer	1.34e-05	8.6e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—JUN—bone cancer	1.33e-05	8.54e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—BRAF—bone cancer	1.31e-05	8.43e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—MMP9—bone cancer	1.29e-05	8.3e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—BRAF—bone cancer	1.29e-05	8.3e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—BRAF—bone cancer	1.29e-05	8.28e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—DHFR—bone cancer	1.29e-05	8.27e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—BRAF—bone cancer	1.29e-05	8.25e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—BRAF—bone cancer	1.28e-05	8.23e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—EGFR—bone cancer	1.27e-05	8.17e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—BRAF—bone cancer	1.27e-05	8.15e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—BRAF—bone cancer	1.27e-05	8.12e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MDM2—bone cancer	1.25e-05	8.05e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—EGFR—bone cancer	1.25e-05	8.04e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—JUN—bone cancer	1.25e-05	8.03e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—EGFR—bone cancer	1.25e-05	8.02e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MDM2—bone cancer	1.25e-05	8.01e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—EGFR—bone cancer	1.25e-05	8e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—EGFR—bone cancer	1.24e-05	7.97e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PTGS2—bone cancer	1.24e-05	7.95e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—EGFR—bone cancer	1.23e-05	7.9e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—EGFR—bone cancer	1.23e-05	7.87e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MMP9—bone cancer	1.22e-05	7.81e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GSTP1—bone cancer	1.21e-05	7.77e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GNA11—bone cancer	1.2e-05	7.73e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MDM2—bone cancer	1.19e-05	7.66e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—EGFR—bone cancer	1.16e-05	7.43e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—EGFR—bone cancer	1.16e-05	7.42e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MDM2—bone cancer	1.1e-05	7.07e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—EGFR—bone cancer	1.09e-05	7.01e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—JUN—bone cancer	1.09e-05	6.99e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—JUN—bone cancer	1.08e-05	6.96e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MDM2—bone cancer	1.08e-05	6.95e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MDM2—bone cancer	1.08e-05	6.94e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MDM2—bone cancer	1.08e-05	6.91e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MDM2—bone cancer	1.07e-05	6.89e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTGS2—bone cancer	1.06e-05	6.84e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MDM2—bone cancer	1.06e-05	6.83e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MDM2—bone cancer	1.06e-05	6.81e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MMP9—bone cancer	1.06e-05	6.8e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MMP9—bone cancer	1.05e-05	6.77e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—EGFR—bone cancer	1.05e-05	6.71e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTGS2—bone cancer	1.04e-05	6.7e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—JUN—bone cancer	1.04e-05	6.66e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MMP9—bone cancer	1.01e-05	6.48e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—EGFR—bone cancer	9.83e-06	6.31e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TP53—bone cancer	9.71e-06	6.24e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TP53—bone cancer	9.7e-06	6.23e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—JUN—bone cancer	9.56e-06	6.14e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—JUN—bone cancer	9.41e-06	6.04e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—JUN—bone cancer	9.39e-06	6.03e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—JUN—bone cancer	9.36e-06	6.01e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GSTP1—bone cancer	9.34e-06	6e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—JUN—bone cancer	9.33e-06	5.99e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MMP9—bone cancer	9.3e-06	5.97e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—JUN—bone cancer	9.24e-06	5.93e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—JUN—bone cancer	9.21e-06	5.92e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—bone cancer	9.16e-06	5.88e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MMP9—bone cancer	9.15e-06	5.88e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MMP9—bone cancer	9.13e-06	5.87e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MMP9—bone cancer	9.11e-06	5.85e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MMP9—bone cancer	9.08e-06	5.83e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MMP9—bone cancer	8.99e-06	5.77e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MMP9—bone cancer	8.96e-06	5.76e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—bone cancer	8.77e-06	5.63e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—EGFR—bone cancer	8.56e-06	5.5e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—EGFR—bone cancer	8.52e-06	5.47e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—bone cancer	8.25e-06	5.3e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—EGFR—bone cancer	8.16e-06	5.24e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTGS2—bone cancer	8.04e-06	5.17e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTGS2—bone cancer	7.85e-06	5.04e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EGFR—bone cancer	7.52e-06	4.83e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTGS2—bone cancer	7.4e-06	4.75e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EGFR—bone cancer	7.4e-06	4.75e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EGFR—bone cancer	7.38e-06	4.74e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EGFR—bone cancer	7.36e-06	4.73e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EGFR—bone cancer	7.33e-06	4.71e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EGFR—bone cancer	7.26e-06	4.66e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EGFR—bone cancer	7.24e-06	4.65e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—bone cancer	7.19e-06	4.62e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—bone cancer	7.15e-06	4.59e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—bone cancer	6.85e-06	4.4e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—bone cancer	6.31e-06	4.05e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTGS2—bone cancer	6.27e-06	4.03e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—bone cancer	6.21e-06	3.99e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—bone cancer	6.2e-06	3.98e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—bone cancer	6.18e-06	3.97e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—bone cancer	6.16e-06	3.95e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—bone cancer	6.1e-06	3.92e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—bone cancer	6.08e-06	3.91e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTGS2—bone cancer	4.84e-06	3.11e-05	CbGpPWpGaD
